The Patent Description & Claims data below is from USPTO Patent Application 20070202163, Fast-

disintegrating epinephrine tablets for buccal or sublingual administration.

1. A pharmaceutical tablet for buccal or sublingual administration comprising: (a) about 0.5% to about
90% epinephrine; (b) about 7.5% to about 95% filler; and (c) about 2.5% to about 10.5% disintegrant
wherein administration of said pharmaceutical tablet provides a multi-phasic pharmacokinetic release
profile of said epinephrine.

2. The pharmaceutical tablet of claim 1, wherein said buccal or sublingual tablet comprises at least
about 15 mg of epinephrine.

3. The pharmaceutical tablet of claim 1, wherein said buccal or sublingual tablet comprises at least
about 20 mg of epinephrine.

4. The pharmaceutical tablet of claim 1, wherein said buccal or sublingual tablet comprises at least
about 30 mg of epinephrine.

5. The pharmaceutical tablet of claim 1, wherein said buccal or sublingual tablet comprises at least
about 40 mg of epinephrine.

6. The pharmaceutical tablet of claim 1, wherein said buccal or sublingual tablet comprises at least
about 60 mg of epinephrine.

7. The pharmaceutical tablet of claim 1, wherein said buccal or sublingual tablet comprises at least
about 80 mg of epinephrine.

8. The pharmaceutical tablet of claim 1, wherein said multi-phasic pharmacokinetic release profile
comprises two or more plasma epinephrine peaks upon in vivo administration of said buccal or
sublingual tablet.

9. The pharmaceutical tablet of claim 1, wherein said multi-phasic pharmacokinetic release profile
comprises three or more plasma epinephrine peaks upon in vivo administration of said buccal or
sublingual tablet.

10. The pharmaceutical tablet of claim 1, wherein said multi-phasic pharmacokinetic release profile
comprises four or more plasma epinephrine peaks upon in vivo administration of said buccal or
sublingual tablet.

11. A pharmaceutical tablet for buccal or sublingual administration comprising: (a) about 0.5% to about
90% epinephrine; (b) about 7.5% to about 95% filler; and (c) about 2.5% to about 10.5% disintegrant
wherein administration of said pharmaceutical tablet provides a sustained-release of a pharmaceutically
effective amount of epinephrine for at least 0.5 hours or more after administration.

12. The pharmaceuticat tablet of claim 11, wherein said buccal or sublingual tablet comprises at least
about 15 mg of epinephrine.

13. The pharmaceutical tablet of claim 11, wherein said buccal or sublingual tablet comprises at least
about 20 mg of epinephrine.

14. The pharmaceutical tablet of claim 11, wherein said buccal or sublingual tablet comprises at least
about 30 mg of epinephrine.

15. The pharmaceutical tablet of claim 11, wherein said buccal or sublingual tablet comprises at least
about 40 mg of epinephrine.

16. The pharmaceutical tablet of claim 11, wherein said buccal or sublingual tablet comprises at least
about 60 mg of epinephrine.

17. The pharmaceutical tablet of claim 11, wherein said buccal or sublingual tablet comprises at least
about 80 mg of epinephrine.

18. The pharmaceutical tablet of claim 11, wherein said buccal or sublingual tablet comprises about 100
mg or more of epinephrine.

19. The pharmaceutical tablet of claim 11, wherein administration of said pharmaceutical tablet
provides a sustained-release of a pharmaceutically effective amount of epinephrine for at least 1 hour or
more after administration.

20. The pharmaceutical tablet of claim 11, wherein administration of said pharmaceutical tablet
provides a sustained-release of a pharmaceutically effective amount of epinephrine for at least 2 hours
or more after administration.

21. The pharmaceutical tablet of claim 11, wherein administration of said pharmaceutical tablet
provides a sustained-release of a pharmaceutically effective amount of epinephrine for at least 3 hours
or more after administration.

22. A pharmaceutical tablet for buccal or sublingual administration comprising: (a) about 0.5% to about
90% epinephrine; (b) about 7.5% to about 95% filler; and (c) about 2.5% to about 10.5% disintegrant
wherein administration of said pharmaceutical tablet provides a pharmacokinetic profile substantially
equivalent to the pharmacokinetic profile of traditional injectable dosage forms comprising epinephrine
administered either intramuscularly or subcutaneously.

23. The pharmaceutical tablet of claim 22, wherein said traditional injectable dosage form comprising
epinephrine is 0.3 mg epinephrine administered intramuscularly.

24. The pharmaceutical tablet of claim 22, wherein said traditional injectable dosage form comprising
epinephrine is 0.3 mg epinephrine administered subcutaneously.

25. The pharmaceutical tablet of claim 22, wherein said traditional injectable dosage form comprising
epinephrine is 0.15 mg epinephrine administered intramuscularly.

26. The pharmaceutical tablet of claim 22, wherein said traditional injectable dosage form comprising
epinephrine is 0.15 mg epinephrine administered subcutaneously.

27. The pharmaceutical tablet of claim 22, wherein said pharmacokinetic profile consists of one or more
of the pharmacokinetic parameters selected from the group consisting of: C.sub.max, T.sub.max,
AUC.sub.(last), and AUC.sub.(0-.infin.).

28. The pharmaceutical tablet of claim 22, wherein said pharmaceutical tablet comprises less than 60
mg of epinephrine.

29. The pharmaceutical tablet of claim 22, wherein said pharmaceutical tablet comprises less than 40
mg of epinephrine.

30. The pharmaceutical tablet of claim 22, wherein said pharmaceutical tablet comprises less than 30
mg of epinephrine.

31. The pharmaceutical tablet of claim 22, wherein said pharmaceutical tablet comprises less than 20
mg of epinephrine.

32. The pharmaceutical tablet of claim 22, wherein said pharmaceutical tablet comprises less than 15
mg of epinephrine.

33. The pharmaceutical tablet of claim 22, wherein said pharmaceutical tablet comprises less than 10
mg of epinephrine.

34. The pharmaceutical tablet of claim 22, wherein said pharmaceutical tablet comprises less than 5 mg
of epinephrine.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Fast-disintegrating epinephrine tablets for buccal or
sublingual administration patent application.